← FDA DRUG APPROVALS
FDA ANDA · ANDA208043
NALTREXONE HYDROCHLORIDE; BUPROPION HYDROCHLORIDE
Sponsor: ACTAVIS LABS FL INC
APPLICATION
ANDA208043
TYPE
ANDA
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
None (Tentative Approval)
Products
NALTREXONE HYDROCHLORIDE; BUPROPION HYDROCHLORIDENone (Tentative Approval)
NALTREXONE HYDROCHLORIDE 8MG/90MG, BUPROPION HYDROCHLORIDE · TABLET, EXTENDED RELEASE · ORAL
Approval history
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.